The Australian Parkinson’s Mission are busy finalising the necessary requirements in order to move to the first intake stage of the clinical trials but wanted to give you an update on the progress of the APM to date.
We are excited to announce that the University of Sydney will join the APM as a partner, joining the Garvan Institute of Medical Research, The Cure Parkinson’s Trust, Shake It Up Australia, Parkinson’s Australia and the Michael J. Fox Foundation. The University of Sydney is one of Australia’s leading higher education and research universities and will bring critical expertise to the program.
With key partnerships finalised, the first patient visits are scheduled to begin in February 2020 (once ethics approval is confirmed) and take place over a year. We are planning to have eight clinics participate in the clinical trial, located in hospitals and clinical centres in NSW, Victoria, Queensland, South Australia and Western Australia.
Once critical organisational aspects of the trial are finalised, we will be alerting you closer to the intake period so you can discuss your suitability as a participant with one of the APM clinical trial site doctors. We expect that this will be in January 2020.
A novel feature for Trial 1, is that it will assess four repurposed medications against placebo, recruiting 300 patients nationwide. These medications each have different but compelling biochemical evidence for their potential to slow or stop long-term decline in Parkinson’s. This trial design will allow the testing of various pathological pathways, such as inflammation and oxidative stress, within one study. The APM researchers will test the target engagement of these pathways, and evaluate disease progression.
The APM strives to transform our understanding of Parkinson’s, identify genetic targets to guide drug development in Australia, and generate the evidence for personalised treatments for patients with Parkinson’s based on each individual’s genetic information.
We will provide further updates as they become available.